Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Bos taurus | Matrix metalloproteinase 13 | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Drosophila melanogaster | Matrix metalloproteinase 1 | Matrix metalloproteinase 13 | 471 aa | 476 aa | 37.8 % |
Echinococcus multilocularis | matrix metallopeptidase 7 (M10 family) | Matrix metalloproteinase 13 | 471 aa | 448 aa | 34.2 % |
Echinococcus granulosus | matrix metallopeptidase 7 M10 family | Matrix metalloproteinase 13 | 471 aa | 448 aa | 34.6 % |
Onchocerca volvulus | Matrix metalloproteinase 13 | 471 aa | 453 aa | 29.8 % | |
Onchocerca volvulus | BCL7-like protein homolog | Matrix metalloproteinase 13 | 471 aa | 489 aa | 27.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma brucei | DNA topoisomerase II alpha, putative | 0.0593 | 0.8769 | 1 |
Toxoplasma gondii | ATPase/histidine kinase/DNA gyrase B/HSP90 domain-containing protein | 0.0217 | 0.1794 | 0.1794 |
Chlamydia trachomatis | DNA gyrase subunit B | 0.0217 | 0.1794 | 0.407 |
Plasmodium vivax | DNA topoisomerase II, putative | 0.0659 | 1 | 1 |
Onchocerca volvulus | Putative DNA topoisomerase 2, mitochondrial | 0.0478 | 0.6637 | 0.5 |
Trypanosoma cruzi | DNA topoisomerase II, putative | 0.0593 | 0.8769 | 1 |
Brugia malayi | Probable DNA topoisomerase II | 0.0659 | 1 | 0.5 |
Mycobacterium tuberculosis | DNA gyrase (subunit B) GyrB (DNA topoisomerase (ATP-hydrolysing)) (DNA topoisomerase II) (type II DNA topoisomerase) | 0.0217 | 0.1794 | 1 |
Loa Loa (eye worm) | TOPoisomerase family member | 0.0659 | 1 | 1 |
Plasmodium falciparum | DNA topoisomerase 2 | 0.0659 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0442 | 0.5976 | 0.5816 |
Wolbachia endosymbiont of Brugia malayi | DNA gyrase, topoisomerase II, B subunit, GyrB | 0.0217 | 0.1794 | 1 |
Plasmodium vivax | DNA gyrase subunit B, putative | 0.0217 | 0.1794 | 0.1794 |
Echinococcus multilocularis | DNA topoisomerase 2 alpha | 0.0659 | 1 | 0.5 |
Trypanosoma cruzi | DNA topoisomerase II, putative | 0.0593 | 0.8769 | 1 |
Echinococcus granulosus | DNA topoisomerase 2 alpha | 0.0659 | 1 | 0.5 |
Onchocerca volvulus | DNA topoisomerase 2 homolog | 0.0478 | 0.6637 | 0.5 |
Trypanosoma brucei | DNA topoisomerase II beta, putative | 0.0593 | 0.8769 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0291 | 0.3176 | 0.2904 |
Treponema pallidum | DNA gyrase, subunit B (gyrB) | 0.0217 | 0.1794 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0442 | 0.5976 | 0.5816 |
Toxoplasma gondii | DNA topoisomerase 2, putative | 0.0659 | 1 | 1 |
Leishmania major | DNA topoisomerase ii | 0.0593 | 0.8769 | 1 |
Giardia lamblia | DNA topoisomerase II | 0.063 | 0.946 | 0.5 |
Entamoeba histolytica | DNA topoisomerase II, putative | 0.0659 | 1 | 0.5 |
Onchocerca volvulus | DNA topoisomerase 2 homolog | 0.0478 | 0.6637 | 0.5 |
Brugia malayi | DNA topoisomerase II, alpha isozyme | 0.0659 | 1 | 0.5 |
Mycobacterium ulcerans | DNA gyrase subunit B | 0.0217 | 0.1794 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0291 | 0.3176 | 0.2904 |
Chlamydia trachomatis | DNA gyrase subunit B | 0.0358 | 0.4407 | 1 |
Trichomonas vaginalis | DNA topoisomerase II, putative | 0.0659 | 1 | 0.5 |
Plasmodium falciparum | DNA gyrase subunit B | 0.0217 | 0.1794 | 0.1794 |
Schistosoma mansoni | DNA topoisomerase II | 0.0659 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 1.5 nM | Inhibitory concentration against MMP-13 of bovine articular cartilage explants | ChEMBL. | 16005220 |
IC50 (binding) | = 1.5 nM | Inhibitory concentration against MMP-13 of bovine articular cartilage explants | ChEMBL. | 16005220 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.